Glenmark rises armed with research after five year hiatus

Glenmark rises armed with research after five year hiatus It’s been a while since Glenmark Pharmaceuticals licensed a drug. Between 2004 and 2011, arguably its best years in research, Glenmark cut as many as seven deals with multinational companies for indigenously developed drugs, which brought in $220 million in payments. Since then, there’s been a lull. The company’s last experimental drug was licensed to Paris headquartered Sanofi in a deal that would have garnered more than $600 million – a record. However, none of these drugs could be developed to secure regulatory approval. Glenmark’s push into innovation — seen as Read More


ˆ Back To Top